The Consortium's clinical programme will take place at clinical sites in London and Edinburgh.  The clinical programme in London will be carried out by Imperial staff working at the Royal Brompton Hospital. Edinburgh's clinical programme will be carried out at the Western General Hospital (adults) and the Royal Hospital for Sick Children (paediatric patients).

Our Clinical Teams

The Royal Brompton Hospital, London cares for both adult and paediatric patients. Our research studies reflect this patient population. The clinical team for the UK CF Gene therapy consortium at the Royal Brompton Hospital is led by Prof Eric Alton.  He is both a researcher and an Honorary Consultant in adult respiratory medicine at the Royal Brompton Hospital. Dr Jane Davies, is a researcher/senior lecturer and an Honorary Consultant in paediatric respiratory medicine. 

Nia Voase is the Clinical Trial Coordinator, and a paediatric nurse by background.  Along with her is research nurse,  Hazmine Mohamedhossen and respiratory physiologist Clare Saunders. If you would like any more information on specific studies, you can email Nia Voase or phone 0207 352 8121 ext 3386.
 

 In Edinburgh the adult clinical team running the trials are Maria Dewar (Research Manager) with two Clinical Fellows Dr Nick Bell and Dr Phil Reid. The clinical lead in Scotland is Dr Alastair Innes supported by Prof Andrew Greening. For more information on specific studies please email
cf-info@ed.ac.uk or  phone 0131 537 2415.

The paediatric clinical research team consists of Dr Kenny Macleod, clinical fellow and Kay Riding, paediatric research nurse. The studies will be led by Dr Steve Cunningham, consultant respiratory paediatrician. If you would like any more information on these studies, you can email Kenny Macleod or phone 0131 536 0827.

Clinical Programme

Tracking Study

Before we can undertake any gene therapy studies, we had to collect information on the assays (tests) we will take to ensure that they will be able to tell whether the Gene Therapy has produced any clinical improvement.

Run-In

We have followed the tracking study with the run-in study, which involves studying CF patients over the course of 18 months.  We will use the assays which have survived the tracking study in order to assess their variability in the CF lung and to determine suitable patients to use for our gene therapy trial. 

Pilot Trial

Prior to our multidose gene therapy trial, we will undertake a single application of gene therapy in our pilot study.  This is primarily for safety but also to assess efficacy of the gene therapy product.  The results of this trial will help us to determine the optimal dose and dosing frequency of gene therapy to take in to the multi dose trial. 

Multi-dose Clinical Trial

We will repeatedly administer the gene therapy product at a dose determined in the pilot trial to CF patients' lungs.  The study will show us whether levels of gene transfer are sufficient to produce clinical benefit. 

For further information and updates on our studies please visit our studies page